Shares of Array BioPharma Inc. (ARRY) are down $1.38, or 20.51%, at $5.35, after after AstraZeneca (AZN) announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint. Antoine Yver, Head of Oncology, Global Medicines Development at AstraZeneca […]
View the full post at: Morning Buzz: Array BioPharma (ARRY), Apple Inc. (AAPL), GoPro, Inc. (GPRO), XOMA (XOMA)